Brief: Ipsen Withdraws Tazverik® (tazemetostat) In Follicular Lymphoma, Epithelioid Sarcoma
09/03/2026 06:04
March 9 (Reuters) - Ipsen SA IPN.PA: IPSEN VOLUNTARILY WITHDRAWS TAZVERIK® (TAZEMETOSTAT) IN FOLLICULAR LYMPHOMA AND EPITHELIOID SARCOMA WORKS WITH U.S. FDA TO EXECUTE TAZVERIK WITHDRAWAL WITHDRAWAL NOT EXPECTED TO IMPACT COMPANY FINANCIAL GUIDANCE IDMC ADVISES RISKS MAY OUTWEIGH BENEFITS DUE TO SECONDARY HEMATOLOGIC MALIGNANCIES Source text: ID:nGNE7PzyTz Further company coverage: IPN.PA (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Ipsen SA
See all newsFulcrum falls after discontinuing sickle cell drug program
Fulcrum falls after discontinuing sickle cell drug program
Fulcrum scraps sickle cell drug program after FDA raises cancer-risk concerns
Fulcrum Therapeutics falls after scrapping sickle cell drug development
Brief: Ipsen's IQIRVO Shows Meaningful Fatigue Improvements In Moderate-To-Severe PBC Patients